DAFTAR PUSTAKA

1. Farid ML. Onkologi ginekologi edisi pertama. Yayasan Bina Sarwono

Prawiroharjo. Jakarta: 469-527.

2. Lalwani N, Prasad SR, Vikran R, Shanbhogue AK, Huettner PC, Fasih N.

Histologic, molecular and cystogenetic features of ovarian cancer impications
for diagnosis and treatment. Radio Graphics. 2011; 31(3): 625-46.

3. Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a rivew.
Cancer Biology Medicine. 2017; 14(1): 9-32.

4. Departemen Kesehatan Republik Indonesia. Situasi penyakit kanker. Pusat

Data Dan Informasi Kementerian Republik Indonesia. 2015.

5. Pemaron. Modifikasi indeks risiko keganasan sebagai modalitas propektive

untuk memprediksi keganasan tumor ovarium [Tesis]. Bali. Fakultas
Kedokteran Universitas Udayana. 2013.

6. Rambe IR. Profil tumor ganas ovarium di laboratorium patologi anatomi

fakultas kedokteran Universitas Andalas Januari 2011 – Desember 2012
[Skripsi]. Padang. Universitas Andalas. 2013National Continence Helpline.
Prolaps. Autralian Government Intiative. 2013.

7. Kurman RJ, Shih LM. The origin and pathogenesis of epithelial ovarian
cancer-a proposed unifiying theory. National Institute of Health. American J
Surgery Pathology. 2010; 34(3): 433-43.

8. Angrraeni A, Darto. Kasus prolpas uteri grade IV, sistokel grade IV dan
rektokel grade III dengan giant vesicolithiasis dan prolaps recti. Departemen
Obstetri dan Ginekologi Fakultas Kedokteran Universitas Sebelas Maret.
2013. 52-8.

9. Australian Government INtiative. Prolapse. National Continence. 2013.

10. Kuncharapu I, Majeroni BA, Johnson DW. Pelvic Organ Prolapse. American
Family Physician. 2010; 81(9): 1111-7.

11. Miedel A, Tegerstedt G, Schmidt MM, Nyren O, Hammarstrom M.

Nonobstetric risk factor for symptomatic pelvic organ prolapse. American
Collage of Obstetricians and Gynecologusts. 2009; 113(5): 1089-97.

12. Persu C, Chapple CR, Cauni V, Gutue S, Geaclete. Pelvic organ prolapse
quantification system (POP-Q) a new era in pelvic prolaps staging, J Medcial
and life. 2011;4(1): 75-81.
13. Jones KA, Harmanli O. Pessary use in pelvic organ prolaps and urinary
incontinence. Medcal Review Obstetri Obstetrics and Gynecology. 2010;3(1).
3-9.

14. Barber M. Pelvic organ prolapse. Center for Urogynecology and Pelvic Floor
Disorder. 2016. 2-9.

15. Walsh CE, Ow LL, Rajamaheswari N, Dwyer PL. The Manchester repair: an
instructional video. International Urogynecology J. 2017; 28(9): 1425-27.
16. Mungenast F, Thalhammer T. Estrogen biosynthesis and action in ovarian
cancer. Fronties in Endocrinology. 2014; 192(5): 1-12.

17. Gajjar K, Ogden G, Mujahid MI, Razvi K. Symptoms and risk factor of
ovarian cancer: a survey in primary care. International Scholarly Research
Network. 2012.

18. Kim HY. Cho MK, Bae EH, Kim SW, Ma SK. Hydronefrosis caused by giant
ovarian cyst. Departmentof Obstetric and Gynecology. Chonnam National
University Medical School. Korea. 2016; 42(4): 848-9.

19. Volpi E, Benardini L, Angeloni M, Gogna P, Intersimone D, Fedeli F. Ovarian

lymphoma and hydronefrosis. J Society Laparoendoscopic Sugeoun. 2013; 17:
668-71.

20. Penaloza DAS, Mendieta LCG. Hydronephrosis secondary to giant ovarian

cystadenoma: report of case. MOJ Anatomy and Physiology. 2018; 5(5): 277-
9.
21. Aiken WD, Mayhew RG, Mitchell S, Stennett M, Johnson P. Ovarian dermoid
cyst causing distal ureteral obstruction. West Indian Medical J. 2015; 64(2):
157-9.
22. Faluvianti IS. Perbedaan fungsi seksual pasien prolapses uteri antara terapi
operatif dan non opertaif [Skripsi]. Surabaya.Fakultas Kedokteran Airlangga.
2016

23. Klis R, Szymkowiak S, Madej A, Blewniewski M, Krzslak A, Froma E, et al.

rate of positive urine cultire and double j catheter colonization on the basis of
microorganism DNA analysis. Central Europian J Urology. 2014; 67(1): 81-5.

24. Altunal N, Willke A, Hamzooglu O. Ureteral stent infecions: a prospective

study. Brazilian J Infectious Disease. 2017; 21(3): 361-4.